EagleClaw Capital Managment LLC Acquires 13,170 Shares of CRISPR Therapeutics AG $CRSP

EagleClaw Capital Managment LLC raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 77.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,220 shares of the company’s stock after buying an additional 13,170 shares during the period. EagleClaw Capital Managment LLC’s holdings in CRISPR Therapeutics were worth $1,672,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Moors & Cabot Inc. raised its holdings in shares of CRISPR Therapeutics by 9.5% during the 3rd quarter. Moors & Cabot Inc. now owns 7,373 shares of the company’s stock valued at $408,000 after buying an additional 641 shares in the last quarter. Russell Investments Group Ltd. lifted its position in CRISPR Therapeutics by 178.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 212,645 shares of the company’s stock worth $11,764,000 after buying an additional 136,379 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in CRISPR Therapeutics by 2.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 24,136 shares of the company’s stock worth $1,338,000 after buying an additional 658 shares during the last quarter. Privium Fund Management B.V. lifted its position in CRISPR Therapeutics by 8.9% in the 3rd quarter. Privium Fund Management B.V. now owns 48,974 shares of the company’s stock worth $2,709,000 after buying an additional 4,000 shares during the last quarter. Finally, Pekin Hardy Strauss Inc. purchased a new stake in CRISPR Therapeutics in the third quarter worth approximately $1,481,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In related news, General Counsel James R. Kasinger sold 1,040 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $49.26, for a total transaction of $51,230.40. Following the completion of the sale, the general counsel owned 95,857 shares of the company’s stock, valued at $4,721,915.82. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Samarth Kulkarni sold 47,837 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the completion of the transaction, the chief executive officer owned 311,899 shares of the company’s stock, valued at approximately $15,526,332.22. The trade was a 13.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 93,558 shares of company stock worth $4,881,663. Corporate insiders own 5.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $42.24 on Friday. CRISPR Therapeutics AG has a 1 year low of $41.75 and a 1 year high of $63.45. The company has a 50-day moving average of $52.09 and a 200 day moving average of $52.54. The company has a current ratio of 16.21, a quick ratio of 16.21 and a debt-to-equity ratio of 0.36.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.09). The firm had revenue of $12.67 million during the quarter, compared to analysts’ expectations of $14.75 million. CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The firm’s revenue was up 1311.1% compared to the same quarter last year. As a group, analysts anticipate that CRISPR Therapeutics AG will post -4.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CRSP. Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Citizens Jmp restated a “market outperform” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Monday, August 31st. UBS Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. They set a “neutral” rating and a $52.00 price target for the company. Citigroup raised their price objective on CRISPR Therapeutics from $88.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Finally, William Blair upgraded CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $72.93.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.